https://www.thepeptidenewsroom.com/two-thirds-of-glp-1-users-reported-nail-changes-but-researchers-say-cause-is-unp/ The Peptide Newsroom en 2026-10-17 Two-Thirds of GLP-1 Users Reported Nail Changes, But Researchers Say Cause Is Unproven https://www.thepeptidenewsroom.com/trump-administration-weighs-easing-peptide-rules-but-fda-scientists-objected-to-/ The Peptide Newsroom en 2026-10-17 Trump Administration Weighs Easing Peptide Rules, But FDA Scientists Objected to the Change https://www.thepeptidenewsroom.com/glp-1-drugs-linked-to-fewer-heart-events-and-deaths-in-serious-mental-illness-co/ The Peptide Newsroom en 2026-10-17 GLP-1 Drugs Linked to Fewer Heart Events and Deaths in Serious Mental Illness Cohort https://www.thepeptidenewsroom.com/neuvera-launches-peptide-g63-skincare-bundle-but-the-cited-trial-tested-another-/ The Peptide Newsroom en 2026-10-16 Neuvera Launches Peptide G63 Skincare Bundle, But the Cited Trial Tested Another Formula https://www.thepeptidenewsroom.com/glp-1-drugs-linked-to-rare-sudden-vision-loss-but-absolute-risk-stays-low/ The Peptide Newsroom en 2026-10-16 GLP-1 Drugs Linked to Rare Sudden Vision Loss, But Absolute Risk Stays Low